Idelalisib is a selective phosphatidylinositol 3-kinase (PI3K) delta inhibitor used as a targeted therapy for certain blood cancers, including follicular lymphoma and chronic lymphocytic leukemia. Pharmaceutical… Read more













Idelalisib is a selective phosphatidylinositol 3-kinase (PI3K) delta inhibitor used as a targeted therapy for certain blood cancers, including follicular lymphoma and chronic lymphocytic leukemia. Pharmaceutical laboratories and research organizations utilize this collection of Idelalisib reference standards to support rigorous analytical testing and quality control protocols. The category includes essential materials for impurity profiling, such as pharmacopeial and non-pharmacopeial impurities, as well as key metabolites like the N-glucuronide derivative. Additionally, researchers rely on stable isotope labelled compounds to serve as internal standards during mass spectrometry-based bioanalytical method validation, ensuring accurate quantification throughout drug development and manufacturing. By providing a comprehensive range of these high-quality compounds, this selection assists in maintaining compliance and precision in the assessment of Idelalisib and its related substance profiles.